Adaptive Biotechnologies (NASDAQ:ADPT) CEO Sells $2,304,963.12 in Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) CEO Chad Robins sold 124,998 shares of the company’s stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $18.44, for a total transaction of $2,304,963.12. Following the completion of the sale, the chief executive officer directly owned 2,459,245 shares in the company, valued at approximately $45,348,477.80. The trade was a 4.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link.

Adaptive Biotechnologies Stock Down 6.5%

Shares of ADPT stock traded down $1.20 during trading on Wednesday, reaching $17.30. 2,165,376 shares of the company’s stock were exchanged, compared to its average volume of 1,987,802. The stock has a market capitalization of $2.64 billion, a PE ratio of -32.04 and a beta of 2.18. Adaptive Biotechnologies Corporation has a twelve month low of $6.26 and a twelve month high of $20.76. The firm’s fifty day moving average price is $17.22 and its 200-day moving average price is $15.14.

Adaptive Biotechnologies (NASDAQ:ADPT) last announced its quarterly earnings results on Wednesday, November 5th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.01. Adaptive Biotechnologies had a negative return on equity of 58.40% and a negative net margin of 31.50%.The business had revenue of $93.97 million during the quarter, compared to the consensus estimate of $58.76 million. During the same quarter last year, the firm posted ($0.22) EPS. The company’s quarterly revenue was up 102.4% on a year-over-year basis. As a group, analysts anticipate that Adaptive Biotechnologies Corporation will post -0.92 EPS for the current fiscal year.

Institutional Investors Weigh In On Adaptive Biotechnologies

Several hedge funds have recently modified their holdings of ADPT. Sound Income Strategies LLC acquired a new position in Adaptive Biotechnologies in the 3rd quarter worth about $30,000. Assetmark Inc. increased its position in Adaptive Biotechnologies by 867.9% in the 4th quarter. Assetmark Inc. now owns 3,020 shares of the company’s stock valued at $49,000 after acquiring an additional 2,708 shares during the period. Smartleaf Asset Management LLC lifted its holdings in shares of Adaptive Biotechnologies by 593.5% during the third quarter. Smartleaf Asset Management LLC now owns 3,939 shares of the company’s stock worth $59,000 after purchasing an additional 3,371 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its holdings in Adaptive Biotechnologies by 26.0% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,419 shares of the company’s stock valued at $120,000 after purchasing an additional 1,532 shares during the period. Finally, Bayforest Capital Ltd acquired a new position in Adaptive Biotechnologies during the 4th quarter worth about $142,000. Institutional investors and hedge funds own 99.17% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research note on Wednesday, January 21st. Guggenheim lifted their price target on shares of Adaptive Biotechnologies from $20.00 to $21.00 and gave the company a “buy” rating in a research report on Monday, January 26th. Morgan Stanley assumed coverage on Adaptive Biotechnologies in a report on Monday, December 1st. They issued an “equal weight” rating and a $21.00 price objective for the company. Wall Street Zen cut shares of Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a research report on Saturday. Finally, BTIG Research upped their price target on shares of Adaptive Biotechnologies from $19.00 to $21.00 and gave the stock a “buy” rating in a report on Thursday, November 6th. Eight research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Adaptive Biotechnologies has a consensus rating of “Moderate Buy” and a consensus target price of $17.22.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.